S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Price, News & Analysis

$1.90
+0.12 (+6.74%)
(As of 03/1/2024 ET)
Today's Range
$1.77
$1.94
50-Day Range
$1.20
$1.93
52-Week Range
$1.15
$3.82
Volume
234,056 shs
Average Volume
582,139 shs
Market Capitalization
$242.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Compass Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
426.3% Upside
$10.00 Price Target
Short Interest
Healthy
2.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.12mentions of Compass Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.33) to ($0.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.47 out of 5 stars

Medical Sector

321st out of 952 stocks

Biological Products, Except Diagnostic Industry

51st out of 157 stocks


CMPX stock logo

About Compass Therapeutics Stock (NASDAQ:CMPX)

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock Price History

CMPX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Compass Therapeutics Inc Ordinary Shares
Compass Therapeutics Provides Corporate Update
Compass Therapeutics Insider Ups Holding During Year
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
TD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)
Compass Therapeutics GAAP EPS of -$0.09
See More Headlines
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/01/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+426.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-39,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
89,240,000
Market Cap
$242.23 million
Optionable
Not Optionable
Beta
0.56
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Vered Bisker-Leib M.D. (Age 52)
    MBA, Ph.D., Chief Executive Officer
    Comp: $806.43k
  • Dr. Thomas J. Schuetz M.D. (Age 63)
    Ph.D., Co-Founder, President of Research & Development and Vice Chair
    Comp: $829.56k
  • Mr. Neil L. Lerner CPA (Age 57)
    Vice President of Finance
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corporate Secretary
  • Anna Gifford
    Communications Manager
  • Dr. Minori Rosales M.D. (Age 61)
    Ph.D., Senior VP & Head of Clinical Development
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations
  • Dr. James Kranz Ph.D.
    VP and Head of Chemistry Manufacturing & Controls














CMPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings
or view top-rated stocks.

What is Compass Therapeutics' stock price target for 2024?

1 brokers have issued 1 year target prices for Compass Therapeutics' shares. Their CMPX share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 426.3% from the stock's current price.
View analysts price targets for CMPX
or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2024?

Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX stock has increased by 21.8% and is now trading at $1.90.
View the best growth stocks for 2024 here
.

Are investors shorting Compass Therapeutics?

Compass Therapeutics saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 1,970,000 shares, a decline of 9.6% from the January 31st total of 2,180,000 shares. Based on an average daily volume of 545,800 shares, the short-interest ratio is currently 3.6 days. Currently, 2.6% of the shares of the stock are sold short.
View Compass Therapeutics' Short Interest
.

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our CMPX earnings forecast
.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02.

When did Compass Therapeutics IPO?

(CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.20%), Blue Owl Capital Holdings LP (2.22%), Northern Trust Corp (0.60%), Monashee Investment Management LLC (0.39%), Braidwell LP (0.25%) and Nuveen Asset Management LLC (0.24%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends
.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPX) was last updated on 3/2/2024 by MarketBeat.com Staff